Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
NCT02570490 · View on ClinicalTrials.gov ↗
Study Summary
Phase 3, randomized, double-blind, multi-center efficacy and safety study to evaluate an oral CEM-102 loading dose regimen compared to oral linezolid in the treatment of subjects with ABSSSI
Conditions Studied
Interventions
- DRUG linezolid
- DRUG sodium fusidate
Study Locations (20)
California
- — Anaheim
- — Bakersfield
- — Buena Park
- — Fountain Valley
- — La Mesa
- — La Palma
- — Long Beach
- — Los Angeles
- — Modesto
- — National City
- — Oceanside
- — Riverside
- — San Diego
- — San Diego
- — San Diego
- — San Diego
- — San Diego
- — San Dimas
- — Stockton
- — Sylmar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 716 participants |
| Start Date | 2015-11 |
| Est. Completion | 2016-11 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02570490
The ClinicalTrials.gov registry entry for NCT02570490 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 716 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arrevus, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Acute Bacterial Skin and Skin Structure Infections appearing as the primary indexed condition, and to 2 interventions — of which linezolid is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT02570490 reports 20 study locations spanning 1 distinct geographic area — top geographies include California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT02570490 about?
NCT02570490 is a clinical study titled "Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections". Phase 3, randomized, double-blind, multi-center efficacy and safety study to evaluate an oral CEM-102 loading dose regimen compared to oral linezolid in the treatment of subjects with ABSSSI
What is the current status of trial NCT02570490?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 716 participants. The study started on 2015-11. Estimated completion is 2016-11.
What conditions does trial NCT02570490 study?
This clinical trial studies the following conditions: Acute Bacterial Skin and Skin Structure Infections. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT02570490?
The interventions under investigation include: linezolid (DRUG), sodium fusidate (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT02570490?
This trial is sponsored by Arrevus, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT02570490 being conducted?
This trial has 20 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.